Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ADC Therapeutics SA ADCT

Healthcare Biotechnology
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The... see more

Recent & Breaking News (NYSE:ADCT)

ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference

Business Wire February 25, 2021

ADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

Business Wire February 4, 2021

ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S.

Business Wire January 7, 2021

ADC Therapeutics to Participate in SternIR Virtual Corporate Access Event

Business Wire January 4, 2021

ADC Therapeutics and Overland Pharma Form Strategic JV to Expand ADC Drugs Development and commercialization in Greater China and Singapore, Advised by MSQ Ventures

Canada NewsWire December 15, 2020

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore

Business Wire December 14, 2020

ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting

Business Wire December 7, 2020

ADC Therapeutics to Host Conference Call Highlighting Data from its Next-Generation Antibody Drug Conjugates Being Presented at the 62nd American Society of Hematology Annual Meeting

Business Wire November 30, 2020

ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Business Wire November 20, 2020

ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights

Business Wire November 12, 2020

ADC Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

Business Wire November 10, 2020

ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020

Business Wire November 5, 2020

ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting

Business Wire November 4, 2020

ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors

Business Wire November 3, 2020

Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)

Business Wire October 30, 2020

ADC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Common Shares

Business Wire October 9, 2020

New Ventures Funds Rebrands as Scientia Ventures

PR Newswire October 2, 2020

ADC Therapeutics Announces Pricing of Public Offering

Business Wire September 23, 2020

ADC Therapeutics Announces Proposed Public Offering

Business Wire September 21, 2020

ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Business Wire September 21, 2020